Stock Market

Novartis to buy Excellergy for up to $2B to boost allergy portfolio

By Bullbit Editorial · March 27, 2026

WhatNovartis is acquiring Excellergy for up to **$2B** to expand its allergy treatment offerings.
WhyThe acquisition aims to strengthen Novartis' position in the allergy market by adding Excellergy's innovative treatments.
SignalThis deal signals Novartis' commitment to investing in its pharmaceutical portfolio and expanding its presence in the allergy sector.
TargetExcellergy's treatments are expected to target specific allergy-related conditions, enhancing Novartis' product lineup.
RiskThe acquisition poses a risk of integration challenges and potential regulatory hurdles for Novartis.